Evaluation of salivary matrix metalloproteinase-9 (MMP-9) level in patients with oral lichen planus before and after treatment with 0.2% triamcinolone mouthwash
Journal of Dental School,
Vol. 40 No. 3 (2022),
12 June 2023
,
Page 111-115
https://doi.org/10.22037/jds.v40i3.40565
Abstract
Objectives Oral lichen planus (OLP) is a chronic mucocutaneous disease, involving the skin and mucous membranes. Although the pathogenesis of OLP is not fully understood, the immune system, genetic and environmental factors, medications, and infections may play an important role in OLP. The level of matrix metalloproteinases (MMPs) is known to increase in pathological conditions, such as squamous cell carcinoma (SCC), as well as inflammatory conditions, such as OLP. If pain and soreness are present, topical corticosteroids (CSs) are the first-line treatment for these patients. This study aimed to evaluate the level of MMP-9 in individuals with OLP before and after treatment with triamcinolone 0.2% mouthwash.
Method This study was conducted on 18 patients with erosive-atrophic OLP. First, 5 mL of unstimulated saliva was collected, and then, triamcinolone 0.2% mouthwash was prescribed to all the patients. After treatment and healing of the lesions, a sample was collected again from the participants. The MMP-9 concentration was quantified in all the samples using an ELISA kit.
Results The mean age of the participants, including five males and 13 females, was 45.7 years in this study. Before treatment, the mean MMP-9 concentration was 1.599 ng/mL, with a standard deviation (SD) of 1.074, while the mean (±SD) level of MMP-9 was 0.933 ng/mL (0.649) after treatment. The mean reduction was estimated at 0.666, with SD of 1.056 (P=0.016).
Conclusion The MMP-9 level was significantly lower after treatment compared to the pretreatment stage. Based on the results, topical CSs, such as triamcinolone, can decrease the level of MMP-9, as a reliable biomarker of OLP severity; therefore, they can diminish inflammation and prevent the dysplastic progression of the disease.
- Oral Lichen Planus
- Saliva
- MMP-9
- Triamcinolone
How to Cite
References
Agha-Hosseini F, Mirzaii-Dizgah I. Serum and saliva collagenase-3 (MMP-13) in patients with oral lichen planus and oral squamous cell carcinoma. Med J Islam Repub Iran. 2015;29:218.
Farzin M, Mardani M, Ghabanchi J, Fattahi MJ, Rezaee M, Heydari ST, et al. Serum level of matrix metalloproteinase-3 in patients with oral lichen planus. Iran Red Crescent Med J. 2012;14(1):10-3.
Lavanya N, Jayanthi P, Rao UK, Ranganathan K. Oral lichen planus: An update on pathogenesis and treatment. J Oral Maxillofac Pathol. 2011;15(2):127-32.
Vanja V. The Role of salivary cytokines in patients with oral lichen planus. J Autacoids. 2014;3(1):e125.
Delavarian Z, Mohtasham N, Javadzadeh Bolouri A, Babakoohi s, Sadr B, Shakeri MT, et al. The expression of tissue matrix metalloproteinase 2 and 9 in erosive and non-erosive oral lichen planus, inflammatory hyperplasia of oral mucosa
by immunohistochemistry. J Cosmet Dermatol. 2010;1(1):7-13.
Glick M. Burket's oral medicine. 13th edition, PMPH USA; 2021. Chap 4:107.
Neville BW, Damm DD, Allen CM, Chi AC. Oral and maxillofacial pathology: 4th edition, Elsevier Health Sciences; 2016. Chap 16:730.
Fathi MS, El Dessouky HF, Breni HA. CD4+CD25+ T regulatory cells and MMP-9 as diagnostic salivary biomarkers in oral lichen planus. Egypt J Immunol. 2013;20(2):39-53.
Zhou XJ, Sugerman PB, Savage NW, Walsh LJ. Matrix metalloproteinases and their inhibitors in oral lichen planus. J Cutan Pathol. 2001;28(2):72-82.
Vajaria BN, Patel KR, Begum R, Shah FD, Patel JB, Joshi GM, et al. Clinical Significance of Salivary Matrix Metalloproteinase-9 in Oral Precancerous Conditions and Oral Cancer. Cancers Review. 2014;1(2):33-44.
Ahadian H, AKHAVAN KA, Vahidi A, Owlia F. Comparison of two corticosteroids mouthwashes in treatment of symptomatic oral lichen planus. 2012.
Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 2006;11:1696-701.
Rai B, Kharb S, Jain R, Anand SC. Biomarkers of periodontitis in oral fluids. J Oral Sci. 2008;50(1):53-6.
Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol. 2006;26(4):299-307.
Mair YH, Jhamb T, Visser MB, Aguirre A, Kramer JM. Sera and salivary matrix metalloproteinases are elevated in patients with vesiculoerosive disease: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121(5):520-9.
Ashkenazi M, Dennison DK. A new method for isolation of salivary neutrophils and determination of their functional activity. J Dent Res. 1989;68(8):1256-61.
Thongprasom K, Dhanuthai K. Steriods in the treatment of lichen planus: a review. J Oral Sci. 2008;50(4):377-85.
Roopashree MR, Gondhalekar RV, Shashikanth MC, George J, Thippeswamy SH, Shukla A. Pathogenesis of oral lichen planus--a review. J Oral Pathol Med. 2010;39(10):729-34.
Otero-Rey EM, Suarez-Alen F, Peñamaria-Mallon M, Lopez-Lopez J, Blanco-Carrion A. Malignant transformation of oral lichen planus by a chronic inflammatory process. Use of topical corticosteroids to prevent this progression? Acta Odontol Scand. 2014;72(8):570-7.
Jayachandran S, Koijam Sashikumar S. Management of oral lichen planus: a clinical study. Jimsa. 2012;25(3):205-8.
Boorghani M, Gholizadeh N, Taghavi Zenouz A, Vatankhah M, Mehdipour M. Oral lichen planus: clinical features, etiology, treatment and management; a review of literature. J Dent Res Dent Clin Dent Prospects. 2010;4(1):3-9.
Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2-13.
Yuan Y, Wang Z, Dong B. [Modulation of matrix metalloproteinase by dexamethasone in airway remodeling in asthmatic rats]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2003;34(4):680-3.
Cincik H, Erkul E, Pinar D, Ipcioglu O, Gungor A, Cekin E, et al. Evaluation of MMP-9 and TIMP-1 Levels of the Patients with Nasal Polyposis After Corticosteroid Therapies. Indian J Otolaryngol Head Neck Surg. 2013;65(Suppl 2):445-9.
Nagase H, Woessner JF, Jr. Matrix metalloproteinases. J Biol Chem. 1999; 274(31):21491-4.
Navazesh M. Methods for collecting saliva. Ann N Y Acad Sci. 1993;694:72-7.
Ghallab NA, Shaker OG. Serum and salivary levels of chemerin and MMP-9 in oral squamous cell carcinoma and oral premalignant lesions. Clin Oral Investig. 2017;21(3):937-47.
Obase Y, Rytilä P, Metso T, Pelkonen AS, Tervahartiala T, Turpeinen M, et al. Effects of inhaled corticosteroids on metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in the airways of asthmatic children. International archives of allergy and immunology. 2010;151(3):247-54.
Tanaka H, Miyazaki N, Oashi K, Tanaka S, Ohmichi M, Abe S. Sputum matrix metalloproteinase-9: tissue inhibitor of metalloproteinase-1 ratio in acute asthma. J Allergy Clin Immunol. 2000;105(5):900-5.
Mattos W, Lim S, Russell R, Jatakanon A, Chung KF, Barnes PJ. Matrix Metalloproteinase-9 Expression in Asthma: Effect of Asthma Severity, Allergen Challenge, and Inhaled Corticosteroids. Chest. 2002;122(5):1543-52.
Weitoft M, Andersson C, Andersson-Sjöland A, Tufvesson E, Bjermer L, Erjefält J, et al. Controlled and uncontrolled asthma display distinct alveolar tissue matrix compositions. Respir Res. 2014;15(1):67.
Grzela K, Zagórska W, Krejner A, Banaszkiewicz A, Litwiniuk M, Kulus M, et al. Inhaled corticosteroids do not reduce initial high activity of matrix metalloproteinase (MMP)-9 in exhaled breath condensates of children with asthma exacerbation: a proof of concept study. Central-European journal of immunology. 2016;41(2):221-7.
Grzela K, Zagorska W, Krejner A, Litwiniuk M, Zawadzka-Krajewska A, Banaszkiewicz A, et al. Prolonged Treatment with Inhaled Corticosteroids does not Normalize High Activity of Matrix Metalloproteinase-9 in Exhaled Breath Condensates of Children with Asthma. Archivum Immunologiae et Therapiae Experimentalis. 2015;63(3):231-7.
Barton AK, Shety T, Bondzio A, Einspanier R, Gehlen H. Metalloproteinases and their inhibitors are influenced by inhalative glucocorticoid therapy in combination with environmental dust reduction in equine recurrent airway obstruction. BMC Vet Res. 2016;12(1):282.
Park SR, Kim SK, Kim SR, Kim D, Kim KW, Hong IS, et al. Noncanonical functions of glucocorticoids: A novel role for glucocorticoids in performing multiple beneficial functions in endometrial stem cells. Cell Death Dis. 2021;12(6):612.
Ke J, Ye J, Li M, Zhu Z. The Role of Matrix Metalloproteinases in Endometriosis: A Potential Target. Biomolecules. 2021;11(11):1739.
Romano F, Arduino PG, Maggiora M, Curmei E, Manavella V, Broccoletti R, et al. Effect of a structured plaque control on MMP-1 and MMP-9 crevicular levels in patients with desquamative gingivitis associated with oral lichen planus. Clin Oral Investig. 2019;23(6):2651-8.
Xia DN, Tan YQ, Yang JY, Zhou G. Omega-3 polyunsaturated fatty acids: a promising approach for the management of oral lichen planus. Inflamm Res. 2020;69(10):989-99.
Han X, Zhang J, Tan Y, Zhou G. Probiotics: A non-conventional therapy for oral lichen planus. Arch Oral Biol. 2017;81:90-6.
D`Avila-Mesquita C, Couto AES, Campos LCB, Vasconcelos TF, Michelon-Barbosa J, Corsi CAC, et al. MMP-2 and MMP-9 levels in plasma are altered and associated with mortality in COVID-19 patients. Biomed Pharmacother. 2021;142:112067.
Yang H, Wu Y, Ma H, Jiang L, Zeng X, Dan H, et al. Possible alternative therapies for oral lichen planus cases refractory to steroid therapies. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121(5):496-509.
Didona D, Caposiena Caro RD, Sequeira Santos AM, Solimani F, Hertl M. Therapeutic strategies for oral lichen planus: State of the art and new insights. Front Med (Lausanne). 2022; 9:997190.
Vincent SD, Fotos PG, Baker KA, Williams TP. Oral lichen planus: the clinical, historical, and therapeutic features of 100 cases. Oral Surg Oral Med Oral Pathol. 1990;70(2):165-71.
- Abstract Viewed: 194 times
- PDF Downloaded: 89 times